View Item 

Show simple item record

Phase II evaluation of piroxantrone in renal cell carcinoma

dc.contributor.authorAllen, Aceen_US
dc.contributor.authorWolf, Michaelen_US
dc.contributor.authorCrawford, E. Daviden_US
dc.contributor.authorDavis, Mellar P.en_US
dc.contributor.authorNatale, Ronald B.en_US
dc.contributor.authorBarnett, Margaret L.en_US
dc.date.accessioned2006-09-11T15:43:12Z
dc.date.available2006-09-11T15:43:12Z
dc.date.issued1992-06en_US
dc.identifier.citationAllen, Ace; Wolf, Michael; Crawford, E. David; Davis, Mellar P.; Natale, Ronald B.; Barnett, Margaret L.; (1992). "Phase II evaluation of piroxantrone in renal cell carcinoma." Investigational New Drugs 10(2): 129-132. <http://hdl.handle.net/2027.42/45142>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45142
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1500267&dopt=citationen_US
dc.description.abstractThe Southwest Oncology Group (SWOG) studied the response rate and toxicity of piroxantrone (150 mg/m 2 q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 32 eligible patients, there were no partial nor complete responses. There were two mixed responses. Significant white cell toxicity, anemia, nausea, and vomiting were observed. Mild or moderate degrees of fever, malaise, and stomatitis occurred. No significant cardiac toxicity was noted. Piroxantrone does not have significant activity as a single agent in advanced renal cell carcinoma.en_US
dc.format.extent268963 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherPiroxantroneen_US
dc.subject.otherRenal Cell Carcinomaen_US
dc.titlePhase II evaluation of piroxantrone in renal cell carcinomaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherUniversity of Kansas Medical Center, Kansas City, KS, USAen_US
dc.contributor.affiliationotherSouthwest Oncology Group Statistical Center, Seattle, WA, USAen_US
dc.contributor.affiliationotherUniversity of Colorado, Denver, CO, USAen_US
dc.contributor.affiliationotherColumbus Oncology Associates, Columbus, OH, USAen_US
dc.contributor.affiliationotherUniversity of Kansas Medical Center, Kansas City, KS, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid1500267en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45142/1/10637_2004_Article_BF00873131.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00873131en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00873131.pdf
Size:
262.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.